{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral mRNA vaccination broadened tumor antigen presentation, including peptides displayed through MHC-I.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "| Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination |",
          "line_ref": "L28"
        },
        {
          "quote": "| Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape |",
          "line_ref": "L29"
        }
      ],
      "caveat": "Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings."
    },
    {
      "claim_id": "C02",
      "claim": "Type I interferon signaling is a key mechanistic requirement for the observed sensitization to checkpoint blockade.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "- Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.",
          "line_ref": "L39"
        },
        {
          "quote": "1. Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.",
          "line_ref": "L42"
        }
      ],
      "caveat": "Mouse model effects may not map one-to-one to all human tumors, limiting certainty about human mechanistic dependence."
    },
    {
      "claim_id": "C03",
      "claim": "mRNA vaccination increased checkpoint relevance and immune infiltration, supporting combination with anti-PD-L1 therapy.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "| PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable |",
          "line_ref": "L32"
        },
        {
          "quote": "| Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy |",
          "line_ref": "L33"
        },
        {
          "quote": "4. PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.",
          "line_ref": "L45"
        }
      ],
      "caveat": "Vaccine-only and ICI-only controls showed limited standalone benefit in low-immunogenic settings, so benefit depends on context."
    },
    {
      "claim_id": "C04",
      "claim": "In the retrospective metastatic cohort, prior SARS-CoV-2 mRNA vaccination was associated with better survival during ICI treatment.",
      "strength": "tentative",
      "evidence": [
        {
          "quote": "| Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |",
          "line_ref": "L30"
        },
        {
          "quote": "- Translational arm: a retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.",
          "line_ref": "L15"
        }
      ],
      "caveat": "The human analysis is retrospective and non-randomized, with variable vaccination timing and heterogeneous tumor/treatment backgrounds."
    }
  ]
}